MedPath

The effect of hydroxychloroquine versus standard drug therapy on the treatment and recurrence of brucellosis

Phase 2
Conditions
Brucellosis.
Brucellosis
Registration Number
IRCT201406299014N37
Lead Sponsor
Vice-chancellor for Research the Technology, Hamadan University of Medical Sciences
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Other
Sex
All
Target Recruitment
176
Inclusion Criteria

(a) patients with sign and symptoms of brucellosis have Wright test of more than 1/160 and 2ME titer more than 1/80; (b) patients with chronic brucellosis who did not responded to standard drug therapy with constant or increased 2ME titer; (c) age of 18 years or older.
Exclusion criteria: (a) being pregnant; (b) having history of porphyria, psoriasis, degenerative macula, hemolytic diseases, gastrointestinal diseases, neurologic diseases, and G6PD deficiency.

Exclusion Criteria

Not provided

Study & Design

Study Type
interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Response to treatment. Timepoint: before treatment and 1, 2, 3, and 5 months later. Method of measurement: based on 2ME titer.
Secondary Outcome Measures
NameTimeMethod
Incidence of probable adverse effects such as hepatitis and visual impairment. Timepoint: at 1, 2, 3, and 5 months after treatment. Method of measurement: through history taking and physical examination.
© Copyright 2025. All Rights Reserved by MedPath